Feb 06, 2015
Sanofi will moderate a roundtable breakout discussion at CHI's Sixth Annual SCOPE: Summit for Clinical Ops Executives at the Hyatt Regency in Orlando, Florida, February 24-26. The roundtable breakout is scheduled on Tuesday, February 24 at 4:00-5:00 p.m.
Jan 28, 2015
World-renowned thought leaders share insights & best practices, discover industry trends and find solutions to current challenges
Jan 06, 2015
Data science leader Martin Leach, Ph.D., will participate at CHI’s Integrated R&D Informatics & Data Sciences conference on Feb. 16-18, 2015, Moscone North Convention Center, San Francisco, CA. This conference is part of the Molecular Med TRI-CON.
Oct 22, 2014
Leading Pharma, Biotech and Academic Researchers Unite to Share Findings for the Role of Circulating microRNA, Exosomes and Microvesicles, Long Non-Coding RNA and Extracellular RNA in Disease
Oct 08, 2014
Over 1,200 biotherapeutics industry experts will convene at this annual event to share insight and perspective on the evolution of biologics, and the generation, characterization, and clinical application of proteins.
Sep 22, 2014
Discussions will include a variety of issues on how to expedite your biologic to the market safely by overcoming immunogenicity assessment challenges, adopting prediction and mitigation approaches, and selecting the right bioassay.
Sep 19, 2014
Tufts, Johns Hopkins, Cornell & UC Berkeley Address Challenges in Capturing the Complex Functions and Interlocking Biological Systems of Living Tissue and Organs in a 3D Model
Sep 11, 2014
CHI’s Inaugural “Targeting Tick-Borne Diseases” provide the latest science in the pathology, diagnostics, preventatives and treatments for researchers in both human and veterinary medicine.
Sep 10, 2014
Preliminary Agenda Announced for Circulating Tumor Cells at Molecular Medicine Tri-Conference. Over 3000 life science and drug discovery professionals will be present in San Francisco February 15 - 20, 2015.
Sep 10, 2014
A conference dedicated to new antibacterial drugs development, both biologics and small molecule, as well as to the market access and pricing for new antibacterial agents.